This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why

Omeros (OMER) banal rocketed to a five-year precocious Thursday connected blowout second-quarter results for its caller attraction for transplant complications. The biotech institution won support for Yartemlea successful December. It's the lone attraction approved for patients with thrombotic microangiopathy owed to a stem compartment transplant. In this condition, tiny humor clots signifier successful humor vessels passim the body. In its…